Abstract
In the last decade, genetic analysis has aided lymphoma classification, alongside traditional phenotypic subdivision. Lymphomas exhibit sex differences in disease incidence and prevalence; therefore, scope existed to explore sex-specific genetic variation.
Harnessing UK Biobank genetic data (185,000 females, 176,000 males), sex-specific genome-wide genetic variation significantly associated with lymphoma subtypes was determined in both autosomal and sex chromosome genes. Sex-specific genetic variation significantly associated with sex-related characteristics was also identified. Functional predictions for those genes containing significant (p<5×10-5) genetic variation was carried out via ViSEAGO. For each lymphoma subtype, approximately 10-12% of the genes containing significantly associated genetic variants were shared between the sexes, highlighting largely sex-specific profiles for lymphoma subtypes.
Significantly associated X chromosome genetic variants were identified for Non-Hodgkin’s lymphoma (NHL) and Diffuse large B-cell lymphoma (DLBCL), such as variants within SYTL5 (in males) and PPP2R3B (in females); genes previously implicated in haematological malignancy biological processes. Additionally, in female NHL patients, a genetic variant mapped to ESR1, the gene coding for oestrogen receptor-α was identified, adding to the body of evidence highlighting the relevance of oestrogen regulation for haematological malignancy subtypes.
Indeed, up to 9.1% of overlap was observed between those genes containing significant genetic variation associated with specific lymphoma subtypes, and those significantly associated with oestrogen level determination. Gene ontology analysis further emphasised functional overlaps between lymphoma and oestrogen level determination in females, highlighting predicted involvement in epigenetic modification, gene expression, and signalling.
This study revealed sex-specific genetic variation significantly associated with lymphoma, as well as hormone level determination, and revealed biological pathways potentially disrupted during lymphoma pathogenesis which are influenced by oestrogen. Exploring these pathways may advance our understanding of the sex-specificities of lymphoma, and may reveal therapeutic targets to advance patient care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project is supported by funding from Health and Social Care Research and Development Division STL/5569/19 (https://research.hscni.net/) (AJM), UK Research and Innovation Medical Research Council MC_PC_20026 (https://www.ukri.org/councils/mrc/) (AJM), Science Foundation Ireland and the Department for the Economy, Northern Ireland partnership award 15/IA/3152 (https://www.economy-ni.gov.uk/investigators-programme-partnership-funded-projects) (AJM, PM). Sponsors or funders did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data was derived from UK Biobank - 21727
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data is available from UK biobank upon request. Association data is available from UK biobank or from the authors upon request.
